Mereo BioPharma

Mereo BioPharma(MREO)

UK - London
Pharmaceutical

Focus: Acquisition & rapid development of drugs

Mereo BioPharma is a life sciences company focused on Acquisition & rapid development of drugs.

OncologyEndocrinologyWomen's HealthRespiratoryNephrology
Funding Stage
PUBLIC
Open Jobs
0

Pipeline & Clinical Trials

Phase 1
Clinical Trials (1)
NCT02005315A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer
Phase 1
Clinical Trials (1)
NCT01952249A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian
Phase 1
Clinical Trials (1)
NCT02298387A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors
Phase 1
Clinical Trials (1)
NCT02722954A Phase 1b Study of Demcizumab Plus Pembrolizumab in Locally Advanced or Metastatic Solid Tumors
Phase 1
OMP-305B83
Cancer Ovaries
Phase 1
Clinical Trials (1)
NCT03030287A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer
Phase 1
Docetaxel
Solid Tumors
Phase 1
Clinical Trials (1)
NCT01957007A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC
Phase 1
OMP-54F28, Paclitaxel and Carboplatin
Ovarian Cancer
Phase 1
Clinical Trials (1)
NCT02092363Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer
Phase 1
Phase 1
Clinical Trials (1)
NCT02482441A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10
Phase 1
OMP-59R5
Solid Tumors
Phase 1
Clinical Trials (1)
NCT01277146A Dose Escalation Study of OMP-59R5 in Subjects With Solid Tumors
Phase 1
Phase 1
Clinical Trials (1)
NCT01189929A Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane® as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer
Phase 1
Clinical Trials (1)
NCT03295942A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors
Phase 1
Phase 1
Clinical Trials (1)
NCT01189942A Study of FOLFIRI Plus OMP-21M18 as 1st or 2nd-line Treatment in Subjects With Metastatic Colorectal Cancer
Phase 1
Clinical Trials (1)
NCT03035253A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer
Phase 1
OMP-21M18
Solid Tumors
Phase 1
Clinical Trials (1)
NCT00744562A Phase 1 Dose Escalation Study of OMP-21M18 in Subjects With Solid Tumors
Phase 1
Phase 1
Clinical Trials (1)
NCT03031691A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer
Phase 1
Clinical Trials (1)
NCT01703572A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies
Phase 1
Clinical Trials (1)
NCT01189968A Study of Carboplatin and Pemetrexed Plus Demcizumab (OMP-21M18) in Subjects With Non-Squamous Non-Small Cell Lung Cancer
Phase 1
OMP-18R5
Solid Tumors
Phase 1
Clinical Trials (1)
NCT01345201A Dose Escalation Study of OMP-18R5 in Subjects With Solid Tumors
Phase 1
Phase 1
Clinical Trials (1)
NCT03119428A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors
Phase 1
OMP-54F28
Solid Tumors
Phase 1
Clinical Trials (1)
NCT01778439A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors
Phase 1
Vantictumab combined with paclitaxel
Metastatic Breast Cancer
Phase 1
Clinical Trials (1)
NCT01973309A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer
Phase 1
Phase 1
Clinical Trials (1)
NCT03498170The Effect of Itraconazole on BCT197 Exposure in Healthy Male Participants
Phase 1
OMP-54F28 with Sorafenib
Hepatocellular Cancer
Phase 1
Clinical Trials (1)
NCT02069145Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer
Phase 1
OMP-54F28, Nab-Paclitaxel and Gemcitabine
Pancreatic Cancer
Phase 1
Clinical Trials (1)
NCT02050178Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer
Phase 1
Phase 1
Clinical Trials (1)
NCT02926326The Effect of Azithromycin on BCT197 Exposure in Healthy Male Volunteers
Phase 1
Phase 1/2
Clinical Trials (1)
NCT03986086MPH966 for Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
Phase 1/2
Clinical Trials (1)
NCT01647828A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT04761198A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors
Phase 1/2
Alvelestat
Covid19
Phase 1/2
Clinical Trials (1)
NCT04539795COVID-19 Study of Safety and Tolerability of Alvelestat
Phase 1/2
Clinical Trials (1)
NCT01859741A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy
Phase 1/2
Clinical Trials (1)
NCT03118570A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804
Phase 2
Clinical Trials (1)
NCT02908074A 6 Month Safety Extension Study of MBGS205
Phase 2
Phase 2
BPS804 20mg/Kg
Osteopenia
Phase 2
Clinical Trials (1)
NCT02259582A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer
Phase 2
Clinical Trials (1)
NCT02730169Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism
Phase 2
Phase 2
Clinical Trials (1)
NCT03636347A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.
Phase 2
Phase 2
Clinical Trials (1)
NCT05312697Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis Imperfecta
Phase 2
Phase 2
Clinical Trials (1)
NCT05715216EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer
Phase 2
Active treatment with a high dose of BGS649
Endometriosis
Phase 2
Investigational new drug company code: BGS649
Obese Hypogonadotropic Hypogonadism
Phase 2
Clinical Trials (1)
NCT03679598Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency
Phase 2
Phase 2
Clinical Trials (1)
NCT02289898Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma
Phase 2
BCT197 Part A
Acute Kidney Injury
Phase 2
Clinical Trials (1)
NCT02700919Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease
Phase 2
Clinical Trials (1)
NCT03216486An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta
Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Founded: 2015
Portfolio: 41 clinical trials
SEC Filings: 2 available

Financials (FY2024)

Revenue
$10M
R&D Spend
$17M(174%)41%
Net Income
-$29M
Cash
$57M